ArticleFrontiers in surgery2026
Poly-L-lactic acid (PLLA) in arm contouring: a prospective and blinded trial of Rennova® Elleva and Sculptra®.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Poly-L-lactic acid (PLLA) is a biostimulatory filler used to improve dermal laxity and contour, yet comparative data between formulations for upper-arm rejuvenation remain scarce. Methods: In this prospective, randomized, blinded split-arm trial, 20 adults received bilateral upper-arm injections with two PLLA formulations (Rennova® Elleva vs. Sculptra®). Outcomes included Subject and Physician Global Aesthetic Improvement Scales (S-GAIS, P-GAIS), ultrasonography (USG), skin elasticity, and transepidermal water loss (TEWL) through Day 120. Histological analyses in ten cases assessed skin thickness, inflammation, and crystalline residues. Results: Both products yielded marked enhancements in skin texture and arm contour with excellent tolerability. S-GAIS scores improved to 2.9 ± 0.67 at Day 120, with no differences between formulations ( Conclusions: This study suggests that both Rennova® Elleva and Sculptra® are effective, well-tolerated PLLA formulations that may be capable of producing meaningful aesthetic and biophysical improvements in upper-arm contour and skin quality within the first 120 days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.